JPRN-jRCTs051200080进行中（未招募）未知
A multicenter, open-label, single-arm study with regard to the efficacy of 10-hydroxy-cis-12-octadecenoic acid on insulin sensitivity in patients with impaired glucose tolerance and mild diabetes mellitus
Ogawa Wataru0 个研究点目标入组 45 人开始时间: 2020年11月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 69age old（—）
- 性别
- All
入选标准
- •1) Patients who are over 20 years and under 69 years at the time of consent acquisition (Regardless of gender)
- •2) Patients with BMI 25 kg/m 2 or more
- •3) Patients with impaired glucose tolerance and with diabetes mellitus 75 g OGTT diagnostic criteria for IGT or who do not use oral hypoglycemic drugs with HbA1c below 7.0%.
- •4) With regard to participation in this examination, patients who gained document consent by their own voluntary intention
排除标准
- •1) Patients with severe hepatic dysfunction
- •2) Patients with severe renal dysfunction
- •3) Patients with cancer
- •4) Patients who are treated with oral or intravenous steroids
- •5) Patients with the medical history of cardiovascular disease
- •6) Pregnant women or patients who may be pregnant or breast-feeding
- •7) Patients who have participated in other clinical trials related to weight loss or who have taken drugs or supplements that lead to weight loss in the last 3 months.
- •8) Patients who lose 5% of their weight within the last 3 months
- •9) Patients whom clinical researchers judged to be inappropriate
研究者
相似试验
进行中（未招募）
不适用
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a treatment period of 52 weeksMedDRA version: 14.1Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2009-017169-53-CZBayer HealthCare AG, Leverkusen, D-51368 Germany100
进行中（未招募）
1 期
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a treatment period of 52 weeks - Visanne Study to assess safety in adolescentsClinically suspected or confirmed endometriosis in post menarche female adolescentsMedDRA version: 12.1Level: LLTClassification code 10014778Term: EndometriosisEUCTR2009-017169-53-FRBayer HelathCare AG, Leverkusen, D-51368 Germany111
进行中（未招募）
不适用
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a treatment period of 52 weeksMedDRA version: 15.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2009-017169-53-FIBayer HealthCare AG, Leverkusen, D-51368 Germany100
进行中（未招募）
不适用
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for thetreatment of endometriosis in adolescents over a treatment period of 52 weeksEUCTR2009-017169-53-DEBayer HealthCare AG100
进行中（未招募）
不适用
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a treatment period of 52 weeksEndometriosisEUCTR2009-017169-53-ATBayer HealthCare AG, Leverkusen, D-51368 Germany100